Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F17%3A00102137" target="_blank" >RIV/00216224:14110/17:00102137 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1080/08880018.2017.1373314" target="_blank" >http://dx.doi.org/10.1080/08880018.2017.1373314</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/08880018.2017.1373314" target="_blank" >10.1080/08880018.2017.1373314</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma

Popis výsledku v původním jazyce

The metronomic therapy concept uses low doses of continuously applied chemotherapeutic, anti-angiogenetic, and immunomodulating drugs. Twenty patients with recurrent and 3 with refractory high-risk neuroblastoma were treated by the metronomic concept using celecoxib, cyclophosphamide, vinblastine, and etoposide for up to 24 months. The outcome was compared to 274 matched patients with a first recurrence from stage 4 neuroblastoma using the variables time from diagnosis to first recurrence, number of organs involved, and MYCN amplification. All were treated with dose-intensive conventional chemotherapy. The study patients experienced 1-3 recurrences and had 1-3 sites involved (osteomedullary, primary tumor, central nervous system, lymph nodes, liver, lungs) before the metronomic therapy started. Two patients in complete remission and three with active refractory disease following recurrence treatment were excluded from the outcome analysis. The curves for secondary event-free and overall survival demonstrated no significant differences.

Název v anglickém jazyce

Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma

Popis výsledku anglicky

The metronomic therapy concept uses low doses of continuously applied chemotherapeutic, anti-angiogenetic, and immunomodulating drugs. Twenty patients with recurrent and 3 with refractory high-risk neuroblastoma were treated by the metronomic concept using celecoxib, cyclophosphamide, vinblastine, and etoposide for up to 24 months. The outcome was compared to 274 matched patients with a first recurrence from stage 4 neuroblastoma using the variables time from diagnosis to first recurrence, number of organs involved, and MYCN amplification. All were treated with dose-intensive conventional chemotherapy. The study patients experienced 1-3 recurrences and had 1-3 sites involved (osteomedullary, primary tumor, central nervous system, lymph nodes, liver, lungs) before the metronomic therapy started. Two patients in complete remission and three with active refractory disease following recurrence treatment were excluded from the outcome analysis. The curves for secondary event-free and overall survival demonstrated no significant differences.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pediatric Hematology and Oncology

ISSN

0888-0018

e-ISSN

1521-0669

Svazek periodika

34

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

308-319

Kód UT WoS článku

000419983600006

EID výsledku v databázi Scopus

2-s2.0-85034232887